Royalty Pharma
110 East 59th Street
33rd Floor
New York
New York
10022
United States
Tel: (212)-883-0200
Fax: (212) 883-2260
Website: http://www.royaltypharma.com/
Email: info@royaltypharma.com
66 articles with Royalty Pharma
-
Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
1/7/2022
Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten.
-
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
-
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
11/22/2021
BioCryst Pharmaceuticals, Inc., Royalty Pharma plc and OMERS Capital Markets, announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing.
-
This week, Berkshire announced that it has scaled back those investments, and completely eliminated its stake in Merck.
-
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
6/2/2021
MorphoSys AG (FSE:MOR) announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion.
-
MorphoSys Pharma's Double Deal: Buys Constellation and Enters Partnership with Royalty Pharma
6/2/2021
MorphoSys Pharma is acquiring Constellation Pharmaceuticals for about $1.7 billion. Here's everything you need to know about this billion dollars deal. -
MSCI Announces Strategic Alliance With Royalty Pharma to Launch Life Sciences Indexes
4/21/2021
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today its collaboration with Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, to expand MSCI’s thematic index suite with the launch of new indexes
-
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
4/8/2021
– Dicerna To Receive $180 Million Upfront and Up to $60 Million in Potential Additional Milestone Payments
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
-
New Ventures Funds Rebrands as Scientia Ventures
10/2/2020
New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com.
-
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
8/7/2020
- Biohaven will receive up to $250 million to fund zavegepant's development in migraine and non-migraine indications - Royalty Pharma to acquire up to a 3% royalty for zavegepant, a 0.4% royalty of Nurtec™ ODT and success-based milestone payments - Royalty Pharma will purchase new Commercial Launch Preferred Equity from Biohaven for a total of $200 million payable between 2021 and 2024, providing additional funding for its CGRP-targeting franchise
-
New Ventures Portfolio Company, Royalty Pharma, Surges On Public Debut
6/25/2020
New Ventures Funds , a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of one of its portfolio companies, Royalty Pharma (NASDAQ:RPRX). The company raised $2.18 billion through the sale of 77,681,670 of its Class A ordinary shares priced at $28.00 per share
-
Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty
6/12/2020
Royalty Pharma Acquires Rights to Agios’ Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments
-
In a regulatory filing, Royalty Pharma indicated plans to offer 70 million shares of stock at a target price range of $25 to $28 per share, which would result in raising up to $1.96 billion for its initial public offering.
-
Royalty Pharma Acquires Royalties on Entyvio® from Massachusetts General Hospital
3/5/2020
Royalty Pharma announced that it has acquired Massachusetts General Hospital's royalty interest in Entyvio for $94 million.
-
Christopher Hite Joins Royalty Pharma
2/28/2020
Royalty Pharma announced today that Chris Hite has agreed to join the Company as Executive Vice President and Vice Chairman.
-
Royalty Pharma Announces Appointment of George Grofik as SVP, Head of Investor Relations and Communications
1/31/2020
Royalty Pharma, the largest acquiror of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, announced today that George Grofik has been appointed Senior Vice President, Head of Investor Relations and Communications.
-
Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme
11/5/2019
Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of tazemetostat, Epizyme Inc.'s (Nasdaq: EPZM) lead investigational agent, outside of Japan, and made an equity investment in Epizyme of $100 million, with options to invest up to an additional $100 million in Epizyme common stock.
-
Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement
11/4/2019
Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies, announced funding agreements with Royalty Pharma and its affiliate Pharmakon Advisors that, in aggregate, could bring in up to $270 million in capital, significantly strengthening Epizyme’s financial position and extending its operating runway into at least 2022.
-
Royalty Pharma Announces Promotions in Finance Team in Anticipation of Next Growth Phase
12/3/2018
- Royalty Pharma is pleased to announce that Susannah Gray has been named Executive Vice President – Finance & Strategy, Terrance Coyne has been promoted to Chief Financial Officer, and Kristin Stafford has been promoted to Chief Accounting Officer.